This trial is a randomized, multicenter, open label phase II clinical study. The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities (atezolizumab adjuvant therapy, nivolumab neoadjuvant therapy, pembrolizumab neoadjuvant+adjuvant therapy) in early-stage resectable NSCLC patients. The enrolled patients are randomly assigned in a 1:1:1 ratio to receive relevant treatment in the three perioperative immunotherapy groups mentioned above, and undergoing short-term pathological efficacy evaluation and long-term prognosis follow-up after surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
atezolizumab adjuvant therapy
nivolumab neoadjuvant therapy
pembrolizumab neoadjuvant+adjuvant therapy
Disease-free survival
the time from randomisation to the date of first recurrence, occurrence of new primary lung cancer, or death from any cause
Time frame: 2 years
Overall survival
the time from randomisation to the date of death from any cause
Time frame: 2 years
Major pathological response
≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.